A number of other research analysts also recently weighed in on DCTH. BTIG Research lowered their price target on Delcath Systems to $19.00 in a report on Tuesday, November 15th. HC Wainwright reduced their price target on Delcath Systems from $25.00 to $19.00 and set a buy rating for the company in a research report on Wednesday, August 10th.
Delcath Systems Price Performance
Shares of DCTH opened at $2.92 on Monday. Delcath Systems has a 52 week low of $2.34 and a 52 week high of $10.24. The firm has a market cap of $25.11 million, a price-to-earnings ratio of -0.77 and a beta of 0.92. The company has a current ratio of 1.28, a quick ratio of 1.15 and a debt-to-equity ratio of 2.55. The stock has a 50 day moving average of $3.03 and a 200-day moving average of $3.82.
Hedge Funds Weigh In On Delcath Systems
Several large investors have recently added to or reduced their stakes in DCTH. Millennium Management LLC bought a new stake in shares of Delcath Systems in the 2nd quarter valued at approximately $40,000. Dimensional Fund Advisors LP acquired a new position in shares of Delcath Systems in the 1st quarter valued at $75,000. CI Investments Inc. acquired a new position in shares of Delcath Systems in the 1st quarter valued at $559,000. Cibc World Market Inc. lifted its stake in shares of Delcath Systems by 4.0% in the 1st quarter. Cibc World Market Inc. now owns 88,751 shares of the company’s stock valued at $568,000 after purchasing an additional 3,432 shares during the period. Finally, Vanguard Group Inc. lifted its stake in shares of Delcath Systems by 5.7% in the 1st quarter. Vanguard Group Inc. now owns 360,900 shares of the company’s stock valued at $2,309,000 after purchasing an additional 19,605 shares during the period. Institutional investors and hedge funds own 26.18% of the company’s stock.
Delcath Systems Company Profile
Delcath Systems, Inc, an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan hydrochloride for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.
- Get a free copy of the StockNews.com research report on Delcath Systems (DCTH)
- Salesforce Cuts Labor, Shows Strong Earnings Despite Challenges
- Microsoft Shares: Is it Time to Back Up the Truck?
- Three CBD Stocks to Dominate a Budding Industry
- Is the 60/40 Portfolio Mix Still in Vogue?
- Institutional Support for Analog Devices Remains High
Receive News & Ratings for Delcath Systems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Delcath Systems and related companies with MarketBeat.com's FREE daily email newsletter.